Little Green Pharma completes Cannatrek merger; terms undisclosed

What Dealroom reported, and what it left out

Little Green Pharma has completed its merger with Cannatrek, according to Dealroom, but the report as syndicated carries no price, exchange ratio or effective date.

Dealroom's headline says the companies completed the merger and that the combination builds a "global cannabis player." That's the full verified record CannIntel has today. Nothing in it names the consideration, the share mechanics or the closing date.

Not yet a complete picture. A completed merger leaves a paper trail, and Little Green Pharma is a listed Australian company, so closing should be documented through its continuous-disclosure announcements on the ASX. CannIntel hasn't reviewed those filings, and we aren't reporting terms we can't source.

Treat "global" with care too. It's a label from a headline, not a measured fact about revenue mix, licences or markets served.

The tax question: on a strict reading, structure decides everything

Whether this merger is tax-efficient depends on how it was structured, and a headline can't tell you that.

Start with what doesn't apply. IRC §280E, the US Internal Revenue Code provision that bars plant-touching cannabis businesses from deducting ordinary operating expenses, has no bearing on a merger of two Australian medical cannabis companies. US readers who reflexively run a 280E analysis on every cannabis deal can skip it here.

The Australian questions are different and just as technical. On a strict reading of the Income Tax Assessment Act 1997, three issues matter:

• Whether target shareholders who received scrip qualify for scrip-for-scrip rollover relief.
• Whether carried-forward tax losses survive the change in ownership, under either the continuity of ownership test or the same business test.
• Whether asset transfers inside the combined group trigger any duty or GST consequences.

Read the second item first. Cannabis balance sheets are loss-heavy, and acquired losses are often the quiet asset in a merger like this. If the same business test fails, that asset shrinks fast.

CannIntel can't say how this deal fares on any of those points. The companies' filings should.

Licences, permits and what operators should check

In Australian medical cannabis, the licence stack is the real asset, and a merger doesn't automatically consolidate it.

Medical cannabis in Australia runs on a layered regulatory structure: cultivation and production permissions under the Narcotic Drugs Act 1967, manufacturing authorizations through the Therapeutic Goods Administration (TGA), and import and export permits for cross-border trade. Those permissions attach to named legal entities. A merger of the parent companies doesn't automatically move or merge them.

That's why the "global player" claim deserves scrutiny. Taxonomy matters here. A group with two licensed entities isn't the same as a single entity holding both sets of permissions, and the tax and compliance treatment differs for each.

For investors and counterparties, the checklist is short:

1. The ASX completion announcement and any scheme or merger documents.
2. Any change-of-control notifications made to regulators.
3. The post-merger group structure, showing which entity holds which licence.
4. Disclosure on tax losses and the basis for carrying them forward.

Supply contracts matter too. Change-of-control clauses in distribution and offtake agreements can give counterparties a right to renegotiate, and a closed merger is the moment those clauses activate.

For full background on this story, see the CannIntel topic hub on the Little Green Pharma and Cannatrek merger, which will carry updates as primary documents surface.

The next signal: the first post-completion disclosure from the combined company on the ASX, which should show the final structure, the licence map and whether tax losses carried across.